

Webcast Alert: Isis Pharmaceuticals Announces Ibis Division Analyst Day Webcast

September 28, 2006

CARLSBAD, Calif.--(BUSINESS WIRE)--Sept. 28, 2006--Isis Pharmaceuticals (NASDAQ: ISIS) announces the following Webcast:

What: Isis Pharmaceuticals' Ibis Division Analyst Day Webcast. Isis Pharmaceuticals management will highlight the Company's Ibis Division and introduce commercial plans for the Ibis T5000 biosensor system. Company officials from our partner, Bruker Daltonics, will also present at the event.

When: October 3, 2006 at 11:30 AM Eastern

Where: <http://www.investorcalendar.com/EventPage.asp?ID=108627> or <http://www.isispharm.com>

How: Live over the Internet -- Simply log on to the web at the address above.

Contact: John Waelti, 312-640-6760 or jwaelti@frbir.com

If you are unable to participate during the live webcast, the call will be available for replay at <http://www.investorcalendar.com/ClientPage.asp?ID=108627> or <http://www.isispharm.com>

This webcast includes forward-looking statements regarding our business, the financial position of Isis Pharmaceuticals, and the therapeutic and commercial potential of Isis' technologies and products in development. Any statement describing Isis' goals, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2005, and its quarterly report on Form 10-Q for the quarter ended June 30, 2006, which are on file with the SEC. Copies of these and other documents are available from the Company.

CONTACT: for Isis Pharmaceuticals
John Waelti, 312-640-6760
jwaelti@frbir.com

SOURCE: Isis Pharmaceuticals